OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017
Reportstack, provider of premium market research reports announces the addition of OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 market report to its offering
The publisher has released its new Opportunity Analyzer report, “Nonalcoholic Steatohepatitis (NASH) – Opportunity Analysis and Forecasts to 2017”. The NASH market is currently deserted and awaits its first NASH-specific therapy. With novel mechanism of action awaiting approval such as: Genfit’s PPAR agonist, GFT505 and Intercept Pharmaceuticals/Dainippon Sumitomo Pharma’s FXR agonist, Obeticholic Acid....
View full press release